Clinical Guides
Smoking and Tobacco Cessation
A source-grounded, India-contextualised guide to helping adults stop smoked and smokeless tobacco through respectful behavioural care, shared pharmacotherapy choices, safety screening, pregnancy-aware counselling, follow-up and realistic access to national quitline services; this educational draft is has been reviewed by the MedNext Clinical Team and is not a personal prescription.
MedNext Academy | 12 min read
Smoking and Tobacco Cessation
A source-grounded, India-contextualised guide to helping adults stop smoked and smokeless tobacco through respectful behavioural care, shared pharmacotherapy choices, safety screening, pregnancy-aware counselling, follow-up and realistic access to national quitline services; this educational draft is has been reviewed by the MedNext Clinical Team and is not a personal prescription.
Summary
Tobacco dependence is a chronic, relapsing health condition, not a failure of character. Ask every patient about smoked and smokeless tobacco, nicotine-containing products, frequency, time to first use, previous quit attempts, withdrawal, triggers and readiness. Offer clear, non-judgemental advice to stop and link it with the person's own goals: breathing, fertility, pregnancy, cardiovascular risk, cancer prevention, money or protecting family members. A brief intervention can take less than three minutes, while more intensive individual, group, telephone or digital support can be added.
The most effective routine approach combines behavioural support with a suitable medicine when there is no contraindication. WHO recommends nicotine replacement therapy (NRT), varenicline, bupropion and cytisine as effective adult cessation options; local licensing, availability and product information must be checked before prescribing. Choose a planned quit date or a supported gradual reduction strategy, explain cravings and withdrawal, and arrange proactive follow-up. Do not promise that one medicine works for everyone or that e-cigarettes are harmless cessation treatment.
This guide does not replace assessment of depression, psychosis, suicidality, alcohol or other drug use, pregnancy, breastfeeding, cardiovascular instability, seizure risk, renal impairment or interacting medicines. India has a National Tobacco Quitline (1800-112-356) and missed-call service (011-22901701), with regional-language counselling reported by the National Tobacco Control Programme. Verify current service details and access locally.
How Common Is It?
Tobacco use includes cigarettes, bidis, cigars, hookah or waterpipe, roll-your-own tobacco, heated products and smokeless forms such as gutkha, khaini, zarda, snuff and chewing tobacco. A cigarette count alone underestimates exposure because nicotine delivery varies by product, inhalation, frequency and concurrent smokeless use. Ask about household and occupational smoke exposure without assuming that a person who does not smoke is free from tobacco harm.
Population prevalence differs across Indian states, age groups, sex, occupation and survey methods. This draft makes no unsupported current prevalence claim. Tobacco use is shaped by availability, stress, marketing, social norms, poverty, mental illness, pain, migration and dependence; these are service-design concerns rather than reasons to blame the patient. Adolescents, pregnant people and people with tuberculosis, COPD, cardiovascular disease, oral lesions or cancer deserve particularly early support.
Relapse is common because cues, withdrawal and social exposure persist after a quit attempt. A lapse is one episode of use, not proof that treatment failed. Ask what happened, remove shame, review the plan and restart promptly. Record tobacco type, quantity, dependence indicators, motivation, treatment offered, quit date, abstinence and follow-up rather than documenting only “counselled.” This creates continuity between primary care, hospitals, dental services, mental-health services and tobacco-cessation centres.
Risk Factors
Dependence risk rises with early initiation, frequent use, high nicotine delivery, using soon after waking, night-time use, morning cravings, previous difficult withdrawal and using more than one tobacco product. Bidi, cigarette and smokeless-product labels do not reliably predict delivered nicotine. Ask how the product is used and whether it is swallowed, inhaled or held in the mouth. Social cues, alcohol, tea or coffee routines, driving, work breaks, loneliness, pain and other tobacco users at home can maintain use.
Assess depression, anxiety, trauma, psychosis, ADHD, alcohol use, cannabis or stimulant use, sleep problems and social stress. Treating coexisting illness and offering practical support can improve cessation; do not defer tobacco care until every psychosocial problem is solved. Screen for pregnancy and breastfeeding privately and respectfully. Ask about medicines whose concentrations can change after smoking stops, especially clozapine, olanzapine, theophylline and warfarin; the interaction is largely due to smoke-induced enzymes, not nicotine itself, and requires prescriber review.
Before bupropion, assess seizure history, eating disorder, abrupt alcohol or sedative withdrawal, bipolar activation and interacting medicines. Before varenicline, review renal function and prior adverse effects. For NRT, assess allergy, significant recent acute coronary syndrome or unstable arrhythmia and obtain clinician advice rather than withholding evidence-based care automatically. Risk assessment should never become a barrier to offering behavioural help and a supervised treatment plan.
Diagnosis
Diagnose tobacco dependence clinically from recurrent use, impaired control, craving, withdrawal, continued use despite harm or unsuccessful attempts to stop. Dependence is not measured by cigarettes per day alone. Use a structured history and document the patient's language, goals and consent.
History
Ask all forms of tobacco and nicotine, product, amount, years, first use after waking, use on waking or at night, triggers, previous quit dates, longest abstinence, withdrawal symptoms, lapses, medicines and what helped. Ask about smoking indoors, children or pregnant household contacts, oral products, alcohol, mental health, pregnancy intention, breastfeeding, cardiovascular and seizure history, kidney disease and current medicines. Explore confidence and readiness without coercion.
Examination
Measure pulse, blood pressure, weight and relevant disease control; examine oral mucosa, teeth, periodontal tissues and suspicious white, red, ulcerated or indurated lesions when tobacco is chewed. Assess respiratory symptoms, cardiovascular status, tremor, agitation, mood, intoxication or withdrawal, and pregnancy-related needs. Examination does not quantify dependence or replace a confidential history.
Investigations
Routine tests are not required to diagnose dependence. Order tests for comorbidity or safety: pregnancy testing when clinically appropriate and consented, renal function before dose decisions for renally cleared therapy, and ECG or acute assessment for unstable cardiac symptoms. Assess COPD, cardiovascular disease, tuberculosis, oral disease, cancer and mental-health risk according to presentation. Carbon-monoxide measurement can support feedback where available but must not delay treatment.
Differential Diagnosis
Distinguish tobacco dependence from occasional social use, nicotine use without clear impairment, withdrawal after stopping, and symptoms caused by another condition. Craving, irritability, poor concentration, restlessness, increased appetite and sleep change can occur in withdrawal, but severe depression, mania, psychosis, delirium, intoxication or suicidality need independent assessment. Do not attribute breathlessness, chest pain, cough, oral ulceration or weight loss to smoking without evaluating dangerous alternatives.
A patient may use tobacco to manage anxiety, pain, low mood or attention symptoms; treating the underlying problem and cessation can proceed together. Alcohol and stimulant use may trigger lapses and increase safety risk. Consider medication-induced symptoms, hyperthyroidism, sleep deprivation and acute cardiopulmonary disease when the presentation is atypical.
Nicotine vaping, heated tobacco and smokeless products are not interchangeable exposures. Evidence, product quality, dependence potential and regulation differ. Ask specifically rather than recording “non-smoker.” A patient who has stopped cigarettes but continues gutkha remains exposed to nicotine and carcinogens. Dual use should prompt a plan for complete tobacco cessation. A lapse after a quit date is not a diagnostic failure: determine whether it is a brief lapse or return to regular use and intensify support accordingly.
Management
Use a person-centred plan: ask, advise, assess readiness, assist and arrange follow-up. Agree a quit date when possible, identify high-risk situations, tell family or trusted supporters, remove tobacco and ashtrays, plan substitutes for hand-to-mouth routines, and rehearse a response to cravings. Use brief repeated counselling, motivational interviewing, telephone support, text or app support and group or individual therapy according to preference and access. Encourage smoke-free homes and workplaces and address domestic violence, food insecurity or work constraints that make quitting harder.
Offer pharmacotherapy to adults who want to quit unless contraindicated, using current Indian product information and a clinician's judgement. NRT may be patch, gum, lozenge or another locally available form; a long-acting form with a short-acting form can be considered for strong dependence. Varenicline reduces rewarding effects and craving; bupropion is a non-nicotine option but has seizure and psychiatric precautions. Cytisine may be relevant where licensed and available. Do not combine or switch medicines casually.
Follow up before the quit date if possible, then within the first week and repeatedly during the first month. Ask about use, withdrawal, adherence, adverse effects, mood, pregnancy, other substances and barriers. If a lapse occurs, provide rapid restart and learn from the trigger. Escalate suicidal thoughts, severe psychiatric symptoms, chest pain, anaphylaxis or serious medicine reactions urgently.
Prescribing Information
Selection is shared and safety-led. NRT supplies nicotine without tobacco smoke and can reduce withdrawal; dose and formulation depend on baseline use, first-cigarette timing, product, pregnancy and local product instructions. Counsel on correct patch placement and gum or lozenge technique, common nausea, hiccups, mouth irritation, vivid dreams or palpitations, and safe storage away from children. A clinician should individualise NRT in pregnancy, breastfeeding, recent acute coronary syndrome or unstable arrhythmia rather than relying on internet dosing.
Varenicline requires gradual dose escalation, adherence counselling and renal-dose review; use the current product label, particularly for severe renal impairment. Discuss nausea, sleep disturbance and vivid dreams, and advise prompt contact for severe mood or behavioural change, suicidal thinking, allergic reaction or skin/mucosal reaction. Bupropion also follows a product-specific titration schedule. Avoid it in seizure disorder, current or past bulimia/anorexia, abrupt alcohol or sedative withdrawal, and with monoamine oxidase inhibitors; review medicines that lower seizure threshold and monitor mood, blood pressure and activation.
Smoking cessation can alter concentrations of clozapine, olanzapine, theophylline and warfarin because smoke, not nicotine, induces metabolism. Arrange medication review when smoking stops or restarts. Do not prescribe medicines as a substitute for assessment, and do not advise patients to keep smoking while waiting for help. Pregnancy decisions require an obstetric or qualified clinician: behavioural support is first-line, and any pharmacotherapy must balance maternal benefit, fetal exposure, dependence severity and local guidance.
When to Refer
Refer to a tobacco-cessation service or trained clinician when dependence is strong, there are repeated unsuccessful attempts, poly-tobacco use, pregnancy, adolescence, serious mental illness, active substance use, major cardiovascular disease, seizure risk, renal impairment, interacting medicines or uncertainty about treatment. Refer oral white or red patches, non-healing ulcers, bleeding, induration, dysphagia, unexplained weight loss or neck nodes through dental, ENT or cancer pathways; do not reassure solely because the patient is trying to quit.
Urgent mental-health assessment is needed for suicidal thoughts, severe depression, mania, psychosis, intoxication with danger, or marked behavioural change after a medicine. Acute chest pain, severe dyspnoea, stroke symptoms or syncope require emergency care rather than a routine cessation appointment. Pregnancy with heavy tobacco use, threatened preterm symptoms or reduced fetal movement needs obstetric care.
In India, the National Tobacco Quitline number is 1800-112-356 and the NTCP page also lists a missed-call number, 011-22901701; confirm current operation, language and local referral before promising access. District tobacco-cessation centres may provide counselling and, where available, free pharmacotherapy. Document the receiving service, urgency, last tobacco use, products, medicines, mental-health status and any safeguarding concern.
Red Flags
Treat chest pain, severe breathlessness, haemoptysis, focal neurological deficit, syncope, severe palpitations or cyanosis as possible acute disease, not simply “smoker's symptoms.” Oral red flags include an ulcer lasting more than two weeks, induration, unexplained bleeding, progressive dysphagia, neck mass, trismus, red or white patch, altered sensation or unexplained weight loss. Arrange urgent evaluation while continuing cessation support.
Safety red flags before or during pharmacotherapy include active suicidal thinking, new mania or psychosis, severe allergic reaction, angioedema, blistering or mucosal rash, seizure, uncontrolled vomiting, severe hypertension, acute coronary syndrome and significant renal deterioration. Bupropion-related seizure risk is an emergency. A patient who becomes confused, agitated or unsafe needs immediate assessment for withdrawal, intoxication, delirium or another medical cause.
In pregnancy, do not shame or abruptly stop prescribed treatment without clinical advice; obtain timely obstetric and cessation support. Children who ingest nicotine products need poison or emergency advice immediately. Keep liquids, gum, lozenges, patches and tobacco away from children and pets. These warnings are not a reason to withhold treatment; they define when supervised care and a higher-acuity pathway are required.
Indian Clinical Context
India's tobacco landscape includes bidis, cigarettes, hookah, chewing tobacco and regional mixtures, so counselling must name the product and ask how it is used. A patient may call gutkha, khaini or zarda “mouth freshener”; explain the dependence and oral-cancer risk without ridicule. Ask about language, literacy, travel, cost, work breaks and family support. Use interpreters or regional-language resources rather than assuming English counselling is understood.
The National Tobacco Control Programme lists a toll-free National Tobacco Quitline at 1800-112-356, a missed-call service at 011-22901701 and tobacco-cessation centres. The service page reports regional-language counselling through satellite centres; availability, opening hours and medicine supply can change, so verify before referral. Do not claim that a drug is free, approved or stocked in every district.
WHO's 2024 adult tobacco-cessation guideline supports brief and intensive behavioural interventions, digital support and pharmacotherapies including NRT, varenicline, bupropion and cytisine. It is global guidance, not a substitute for Indian product labels, pregnancy guidance or local antimicrobial and mental-health pathways. NMC mapping is indirect through community medicine, pharmacology, psychiatry and medicine competencies; exact codes must be checked against the current CBME curriculum. This draft has been reviewed by the MedNext Clinical Team and reviewed.
NMC Competency Mapping
Smoking cessation is a cross-disciplinary skill rather than a single diagnosis code. Relevant learning includes taking a respectful risk-factor history, counselling on health promotion and prevention, recognising nicotine withdrawal, prescribing safely, identifying psychiatric and cardiovascular comorbidity, and applying pharmacology to adverse effects and interactions. Exact NMC competency identifiers should be verified against the current CBME Curriculum 2024 and institutional logbook; this guide deliberately does not invent a code.
At Know How level, learners should explain dependence, withdrawal, tobacco harms, the role of behavioural support and the differences between NRT, varenicline, bupropion and cytisine. At Show How level, they should conduct a brief intervention, agree a quit plan, screen pregnancy, seizures, mood and interacting medicines, teach NRT technique and document follow-up. They should recognise oral-cancer, acute cardiopulmonary, psychiatric and paediatric-ingestion red flags.
Assessment should reward non-stigmatising communication, shared decisions, current-formulary checking and escalation, not a memorised universal dose. Students should distinguish smoke-enzyme interactions from nicotine effects, understand that relapse is common, and connect patients to India's quitline or a local cessation service without promising access that has not been checked.
Key Exam Pearls for NEET PG
Tobacco dependence is diagnosed clinically; cigarettes per day alone are insufficient. Ask time to first use, withdrawal, cravings, failed attempts and all smoked and smokeless products. A lapse is not the same as relapse. Brief advice plus behavioural support and pharmacotherapy improves cessation compared with unsupported advice. WHO recognises NRT, varenicline, bupropion and cytisine as effective adult options, subject to local licensing and safety review.
NRT treats withdrawal without tobacco smoke. Varenicline needs renal and adverse-effect review. Bupropion is contraindicated with seizure disorder, eating disorders, abrupt alcohol or sedative withdrawal and MAO-inhibitor use. Smoking cessation can raise clozapine, olanzapine, theophylline and warfarin exposure because smoke induces enzymes; monitor and adjust with the responsible prescriber. Pregnancy requires behavioural support and individualised clinician review.
Always assess depression, suicidality, psychosis, alcohol and other substances. Oral ulcer, red or white patch, induration, dysphagia, neck node, haemoptysis, chest pain and severe dyspnoea are not routine withdrawal. In India remember the NTCP quitline 1800-112-356 and missed-call 011-22901701, but verify current access. Follow-up within the first week and throughout the first month is an intervention, not an administrative extra.
Frequently Asked Questions
Should every tobacco user receive a medicine immediately?
No. Ask what the person wants, assess dependence and safety, then offer a shared plan. Behavioural support is appropriate for everyone; pharmacotherapy is often useful for adults who want to quit but must be individualised for pregnancy, breastfeeding, kidney disease, recent acute coronary syndrome, seizures, eating disorders, mental-health instability and interacting medicines. A medicine does not replace follow-up, trigger planning or treatment of alcohol and other substance use. Use current Indian product information and do not promise a universal dose or guaranteed success.
Is nicotine replacement unsafe after a heart attack or during pregnancy?
Do not make an automatic yes-or-no rule from a leaflet or internet post. Behavioural support is essential, and a clinician should balance the severity of dependence, continued tobacco exposure, time since the cardiac event, arrhythmia status, pregnancy or breastfeeding, formulation and local guidance. Recent acute coronary syndrome or unstable arrhythmia merits medical review before NRT. Pregnancy decisions should involve an obstetric or qualified cessation clinician; avoid shame and avoid abrupt unsupervised changes to prescribed treatment.
What if a patient smokes again after the quit date?
Treat it as information, not moral failure. Ask which product was used, how much, what trigger or mood preceded it, and whether smoking has returned to a regular pattern. Remove remaining tobacco, renew the quit date, rehearse a coping response and intensify telephone, digital or face-to-face support. Recheck adherence and adverse effects, alcohol or other drug use, depression and household exposure. A lapse does not automatically require a different medicine, but repeated lapses should prompt a fuller dependence and safety review.
How can someone in India access cessation help?
The National Tobacco Control Programme lists the National Tobacco Quitline at 1800-112-356 and a missed-call service at 011-22901701, with regional-language counselling through listed centres. Verify the current number, hours, language, district referral and medicine availability before promising a service. Ask a primary-care, district-hospital, dental, TB, respiratory or mental-health team about tobacco-cessation support. Document the referral and provide an urgent route for suicidal thoughts, chest pain, severe breathlessness or serious medicine reactions.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic